New Listings and Changes 1 May 2011

ADDITIONS

Additions - Items

1089H Atropine, Injection containing atropine sulfate 600 micrograms in 1 mL (Pfizer Australia Pty Ltd)
3453R Atropine, Injection containing atropine sulfate 600 micrograms in 1 mL (Pfizer Australia Pty Ltd) (Emergency Drug Supply)
5022H Atropine, Injection containing atropine sulfate 600 micrograms in 1 mL (Pfizer Australia Pty Ltd) (Dental)

Atropine sulfate is used to reduce body secretions, such as saliva, during surgery. It is also used after surgery to reverse the effects of other medicines to prevent muscles from moving during an operation.

At the request of the previous supplier, AstraZeneca Pty Ltd, atropine sulfate was removed from the PBS on 1 December 2010. The PBAC (November 2010) considered that there was a clinical need for atropine sulfate injection and therefore requested that this drug remain listed on the PBS. An alternative supplier, Pfizer Pty Ltd, was found for this drug.

8967Y Docetaxel, Solution concentrate for I.V. infusion 160 mg in 16 mL (DBL Docetaxel Concentrated Injection Mono®)

The PBAC (March 2011) recommended the listing of a higher strength of DBL Docetaxel Concentrated Injection .  Docetaxel is used to treat a range of cancers, including: cancer of the oral cavity and larynx ; breast cancer; ovarian cancer; and non-small cell lung cancer.

8968B Interferon Beta-1a, Injection 44 micrograms (12,000,000 i.u.) in 0.5 mL single dose autoinjector (Rebif 44®)

The PBAC (March 2011) recommended the listing of a new form of injector for interferon beta 1-a for the treatment of multiple sclerosis.

8970D Levodopa with Carbidopa, Intestinal gel 20 mg - 5 mg per mL, 100 mL (Duodopa®)

Refer to ‘Section 100 Additions-Items’ below which includes details for both the Section 85 and Section 100 listings for Duodopa.

Additions - Notes

5453B Pancreatic Extract, Granules (enteric coated) providing not less than 5,000 BP units of lipase activity per 100 mg, 20 g

The following note has been added to the restriction for this item so that it can now be prescribed by Nurse Practitioners:
“For prescribing by nurse practitioners as continuing therapy only, where the treatment of, and prescribing of medicine for, a patient has been initiated by a medical practitioner. Further information can be found in the Explanatory Notes for Nurse Practitioners”.

Alterations – Maximum Quantity

5064M Morphine Sulfate, Capsule 30 mg (controlled release) (MS Mono®) (Dental)
5065N Morphine Sulfate, Capsule 60 mg (controlled release) (MS Mono®) (Dental)
8491X Morphine Sulfate, Capsule 30 mg (controlled release) (MS Mono®)
8492Y Morphine Sulfate, Capsule 60 mg (controlled release) (MS Mono®)
8493B Morphine Sulfate, Capsule 90 mg (controlled release) (MS Mono®)
8494C Morphine Sulfate, Capsule 120 mg (controlled release) (MS Mono®)

The maximum quantity for the above items is being altered from 10 to 14.

1653B Morphine Sulfate, Tablet 10 mg (controlled release) (Momex SR 10, MS Contin®)
1654C Morphine Sulfate, Tablet 30 mg (controlled release) (Momex SR 30, MS Contin®)
1655D Morphine Sulfate, Tablet 60 mg (controlled release) (Momex SR 60, MS Contin®)
1656E Morphine Sulfate, Tablet 100 mg (controlled release) (Momex SR 100, MS Contin®)
5161P Morphine Sulfate, Tablet 15 mg (controlled release) (MS Contin®) (Dental)
5162Q Morphine Sulfate, Tablet 5 mg (controlled release) (MS Contin®) (Dental)
5164T Morphine Sulfate, Tablet 10 mg (controlled release) (Momex SR 10, MS Contin®) (Dental)
5165W Morphine Sulfate, Tablet 30 mg (controlled release) (Momex SR 30, MS Contin®) (Dental)
5166X Morphine Sulfate, Tablet 60 mg (controlled release) (Momex SR 60, MS Contin®) (Dental)
5167Y Morphine Sulfate, Tablet 100 mg (controlled release) (Momex SR 100, MS Contin®) (Dental)
5171E Morphine Sulfate, Sachet containing controlled release granules for oral suspension, 20 mg per sachet (MS Contin Suspension 20 mg®) (Dental)
5243Y Morphine Sulfate, Sachet containing controlled release granules for oral suspension, 30 mg per sachet (MS Contin Suspension 30 mg®) (Dental)
5244B Morphine Sulfate, Sachet containing controlled release granules for oral suspension, 60 mg per sachet (MS Contin Suspension 60 mg®) (Dental)
5245C Morphine Sulfate, Sachet containing controlled release granules for oral suspension, 100 mg per sachet (MS Contin Suspension 100 mg®) (Dental)
5391R Morphine Sulfate, Tablet 200 mg (controlled release) (MS Contin®) (Palliative Care)
5392T Morphine Sulfate, Tablet 200 mg (controlled release) (MS Contin®) (Palliative Care)
8035X Morphine Sulfate, Tablet 5 mg (controlled release) (MS Contin®)
8453X Morphine Sulfate, Tablet 200 mg (controlled release) (MS Contin®)
8489T Morphine Sulfate, Tablet 15 mg (controlled release) (MS Contin®)
8490W Morphine Sulfate, Sachet containing controlled release granules for oral suspension, 20 mg per sachet (MS Contin Suspension 20 mg®)
8146R Morphine Sulfate, Sachet containing controlled release granules for oral suspension, 30 mg per sachet (MS Contin Suspension 30 mg®)
8305D Morphine Sulfate, Sachet containing controlled release granules for oral suspension, 60 mg per sachet (MS Contin Suspension 60 mg®)
8306E Morphine Sulfate, Sachet containing controlled release granules for oral suspension, 100 mg per sachet (MS Contin Suspension 100 mg®)
8545Y Morphine Sulfate, Sachet containing controlled release granules for oral suspension, 200 mg per sachet (MS Contin Suspension 200 mg®)

The maximum quantity for the above items is being altered from 20 to 28.

SECTION 100 – HIGHLY SPECIALISED DRUGS

Additions – Items

8970D Levodopa with Carbidopa, Intestinal gel 20 mg - 5 mg per mL, 100 mL (Duodopa®)

The PBAC (November 2011) recommended the listing of levodopa with carbidopa intestinal gel on the PBS as a Section 100 (Highly Specialised Drug) for the management of advanced Parkinson disease in a patient with severe disabling motor fluctuations not adequately controlled by oral therapy and as a Section 85 listing for maintenance therapy.

The listing of levodopa with carbidopa was previously announced by the Minister for Health and Ageing in a media release dated 25 February 2011.